W
PBYI icon

WealthCollab’s Puma Biotechnology PBYI Stock Holding History

WealthCollab’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.39K Hold
1,156
– – ﹤0.01% 610
2025
Q4 		$6.88K Hold
1,156
– – ﹤0.01% 646
2025
Q3 		$6.14K Hold
1,156
– – ﹤0.01% 636
2025
Q2 		$3.97K Buy
1,156
+845
+272% +$2.7K ﹤0.01% 685
2025
Q1 		$921 Buy
+311
New +$973 ﹤0.01% 847

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

WealthCollab's PBYI Position: Q1 2026 in Review

WealthCollab held its Puma Biotechnology (PBYI) position steady in Q1 2026 at 1,156 shares worth $7.39K. The position accounts for ﹤0.01% of the portfolio, ranked #610.

WealthCollab first reported a position in PBYI in Q1 2025 and has held it in 5 quarters since. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • WealthCollab held 1,156 shares of Puma Biotechnology worth $7.39K as of Q1 2026.
  • WealthCollab left its Puma Biotechnology share count unchanged in Q1 2026.
  • Puma Biotechnology made up ﹤0.01% of WealthCollab's portfolio in Q1 2026, its #610 holding.
  • WealthCollab first reported a position in Puma Biotechnology in Q1 2025 and has held it in 5 quarters since.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on WealthCollab's 13F filing for Q1 2026, filed 13 May 2026.